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Background: Unsafe injection practices contribute to increased risks of blood-borne infections, including human
immunodeficiency virus, hepatitis B and hepatitis C viruses. The aim of this study was to estimate the prevalence
of medical injections as well as assess the level of access to sterile injection equipment by demographic factors
in low- and middle-income countries (LMICs).
Methods: We carried out a meta-analysis of nationally representative Demographic and Health Surveys (DHSs)
conducted between 2010 and 2017 in 39 LMICs. Random effects meta-analysis was used in estimating pooled
and disaggregated prevalence. All analyses were conducted using Stata version 14 and Microsoft Excel 2016.
Results: The pooled 12-month prevalence estimate of medical injection was 32.4% (95% confidence interval
29.3–35.6). Pakistan, Rwanda and Myanmar had the highest prevalence of medical injection: 59.1%, 56.4%
and 53.0%, respectively. Regionally, the prevalence of medical injection ranged from 13.5% in west Asia to
42.7% in south and southeast Asia. The pooled prevalence of access to sterile injection equipment was 96.5%,
with Pakistan, Comoros and Afghanistan having comparatively less prevalence: 86.0%, 90.3% and 90.9%,
respectively.
Conclusions: Overuse of medical injection and potentially unsafe injection practices remain a considerable
challenge in LMICs. To stem the tides of these challenges, national governments of LMICs need to initiate
appropriate interventions, including education of stakeholders, and equity in access to quality healthcare
services.
Keywords: blood-borne infections, low- and middle-income countries, medical injection, sterile injection equipment
Introduction
Injections are one of the most common medical procedures
performed in healthcare settings worldwide.1 About 16 billion
injections are administered annually.1 The majority of these
injections, approximately 90%, are given to administer medicines
for therapeutic purposes, while injections for vaccination and
other procedures such as blood transfusions and injectable con-
traceptives account for the remaining 10%.1 In many instances
where injections are administered for therapeutic purposes,
they are usually unnecessary or could be replaced by oral
medications.1,2 A number of factors contribute to this overuse,
including the misconception that injections are more effective
than oral medications and the financial gains associated with the
use of injections, as they increase the fees healthcare providers
charge for their services.3
A safe injection is one that does not harm the patient receiving
it, does not expose the healthcare provider to any preventable
risk and does not result in waste that is dangerous for the
community.1 Unsafe injection practices such as reusing nee-
dles and syringes and poor handling and disposal of used
injection equipment are related to overuse of or unnecessary
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injections.4–6 These practices portend great health risks for
patients, healthcare workers and the community at large.7 The
health risks include direct exposure to blood-borne diseases
and/or increased chances of needlestick injury and subsequent
exposure to blood-borne infections,2,8,9 all contributing to the
global burden of diseases.10 For instance, available data show
that injection medication is a major contributor to the increasing
trends of new human immunodeficiency virus (HIV) infections
in many countries around the world.11,12 Other blood-borne
infections, particularly, hepatitis B virus, hepatitis C virus and
viral haemorrhagic fever viruses, are similarly and commonly
transmitted through unsafe injections.1,2,6,13
In several low- and middle-income countries (LMICs), espe-
cially the Eastern Mediterranean and Southeast Asia regions, evi-
dence confirms both unnecessary and unsafe use of
injections.2,3,14 However, little is known about the prevalence
of medical injections and access to sterile injection equipment
in LMICs. Worldwide, the prevalence of unsafe injections was
estimated to have decreased from 39% in 2000 to 5% in 2010.2,5
Conversely, in 2010, up to 1.7 million hepatitis B virus infections,
315 000 hepatitis C virus infections and 33 800 HIV infections
were estimated to have occurred due to unsafe injections.5 The
World Health Organization’s (WHO) report on global hepatitis
identified the need for more recent data to monitor progress
towards injection safety since 2010.2 Accordingly, we utilized
data from nationally representative household surveys (2010–
2017) to provide an up-to-date estimate of the prevalence of
medical injections and access to sterile injection equipment in
LMICs by demographic factors.
Methods
Data source
This study utilized data from the Demographic and Health Survey
(DHS) reports of LMICs. The DHSs are nationally representative
household surveys conducted by ICF Macro/MEASURE DHS
on behalf of national ministries of health of the respective
countries. The data and reports are freely available and accessible
from the DHS website (https://dhsprogram.com/data/data-
collection.cfm). Many international partners, including the US
Agency for International Development, provide financial support
for the surveys.15 The standard DHS uses identical methodology
including the probability sampling strategy and survey instru-
ment to collect data that are comparable across countries.15
Our study included reports of countries whose surveys were
conducted from 2010 to 2017 and contained data on the
prevalence of medical injections among adults 15–49 y of age
and access to syringes and needles taken from new, unopened
packages. This study was based on a secondary analysis of
data extracted from DHS reports in LMICs. The variables from
the DHS reports, extracted and included in our analysis, were
the prevalence of medical injection by demographic category,
including sex (male, female), age group (15–24, 25–29, 30–39,
40–49 y), place of residence (rural, urban), education level (no
education, primary, secondary/higher) and wealth index (lowest,
second, middle, fourth, highest). The data in the reports were
completely anonymized. No additional ethical clearance was
required for the conduct of the present study.
Figure 1. PRISMA flow chart for country selection.
Definition of outcome variables
In the DHS, a medical injection was considered to be an injection
given by a healthcare worker, which can be a doctor, nurse,
pharmacist, dentist or other healthcare professionals. The preva-
lence of medical injections was estimated as the proportion of
adults who received an injection from a healthcare worker in
the 12 months preceding the survey. Participants in the surveys
were asked if their last injection was given with a new, unopened
syringe package, and responses to this question were used in
estimating access to sterile injection equipment.
Selection of countries and inclusion criteria
The Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) guidelines16 were followed in select-
ing the countries included in this study (Figure 1). Countries
were included if they are classified as an LMIC by the World
Bank (https://data.worldbank.org/income-level/low-and-middle-
income) and had a DHS conducted from 2010 to 2017 with
medical injection indicators.15 This study period was selected to
provide the most recent update on the subject using available
nationally representative data. We excluded from our study
countries without DHS data or whose DHS data did not measure
the prevalence of medical injection.
Data analysis
Data were analysed using Stata version 14 (StataCorp, College
Station, TX, USA) and Excel 2016 (Microsoft, Redmond, WA, USA).
The proportions of participants whose last injection was admin-
istered using a syringe from a new, unopened package were also
extracted by demographic category. Countries whose reports
were extracted were classified by geographic region according
to the DHS regional classification (Table 1). Furthermore, we
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Table 1. Prevalence of medical injection and access to sterile injection equipment by country
Countries Study period No. of participants Average injections/
person/year
Prevalence of medical
injection, % (95% CI)
Access to new syringe and
needle, % (95% CI)
Sub-Saharan Africa
Benin 2011–2012 21 032 0.5 15.8 (15.3–16.3) 95.0 (94.3–95.8)
Burkina Faso 2010 23 587 0.6 31.6 (31.0–32.2) 99.0 (98.8–99.3)
Burundi 2010 13 149 0.9 33.9 (33.1–34.7) 98.7 (98.3–99.0)
Cameroun 2011 13 912 1.8 40.3 (39.5–41.1) 97.7 (97.4–98.1)
Chad 2014–2015 10 900 1.9 36.0 (35.1–36.9) 93.9 (93.1–94.7)
Comoros 2012 7328 0.6 20.0 (19.1–20.9) 90.3 (88.8–91.8)
Congo 2011–2012 15 542 1.8 25.5 (24.8–26.1) 98.1 (97.7–98.5)




2013–2014 26 582 3.3 32.8 (32.3–33.4) 92.8 (92.2–93.3)
Equatorial Guinea 2011 5132 2.7 38.2 (36.8–39.5) 96.0 (95.1–96.9)
Ethiopia 2011 29 349 1.4 32.7 (32.1–33.2) 97.5 (97.2–97.8)
Gabon 2012 13 530 1.2 32.8 (32.0–33.6) 97.3 (96.8–97.7)
Gambia 2013 13 810 0.8 31.6 (30.8–32.4) 97.1 (96.6–97.6)
Ghana 2014 13 265 0.7 29.4 (28.6–30.2) 97.8 (97.3–98.2)
Kenya 2014 26 688 1.4 40.0 (39.4–40.6) 98.5 (98.3–98.7)
Lesotho 2014 9281 0.9 29.2 (28.3–30.1) 96.9 (96.3–97.6)
Liberia 2013 13 357 1.6 40.2 (39.4–41.1) 98.2 (97.8–98.5)
Mali 2012–2013 14 220 0.7 21.9 (21.3–22.6) 97.5 (96.9–98.0)
Mozambique 2011 17 257 0.5 18.1 (17.5–18.6) 94.2 (93.4–95.0)
Namibia 2013 13 197 1.0 30.5 (29.7–31.3) 97.5 (97.0–98.0)
Niger 2012 14 549 0.8 37.1 (36.3–37.9) 96.4 (95.9–96.9)
Nigeria 2013 56 307 1.1 25.0 (24.7–25.4) 97.1 (96.8–97.3)
Rwanda 2014–2015 19 074 1.4 56.4 (55.7–57.1) 99.2 (99.0–99.4)
Sierra Leone 2013 23 240 1.9 40.0 (39.4–40.6) 97.2 (96.8––97.5)
Tanzania 2015–2016 16 780 1.0 28.5 (27.8–29.2) 98.3 (98.0–98.7)
Togo 2013–2014 13 498 1.2 30.1 (29.4–30.9) 95.9 (95.3–96.5)
Uganda 2011 10 847 1.7 39.5 (38.5–40.4) 96.5 (96.0–97.1)
Zambia 2013–2014 29 972 0.7 22.7 (22.2–23.1) 97.2 (96.9–97.6)
Zimbabwe 2015 17 996 0.5 23.3 (22.7–23.9) 97.8 (97.3–98.2)
South and Southeast Asia
Afghanistan 2015 40 221 2.9 33.8 (33.4–34.3) 90.9 (90.4–91.4)
Cambodia 2014 22 768 1.9 35.0 (34.4–35.6) 98.6 (98.3–98.9)
Indonesia 2012 54 913 1.6 42.9 (42.5–43.3) 93.0 (92.6–93.2)
Myanmar 2015–2016 17 622 2.3 53.0 (52.3–53.8) 98.8 (98.6–99.1)
Nepal 2011 16 795 1.1 32.3 (31.6–33.0) 98.0 (97.6–98.4)
Pakistan 2012–2013 16 692 5.3 59.1 (58.4–60.0) 86.0 (85.3–86.7)
West Asia
Armenia 2015–2016 8871 1.2 13.5 (12.8–14.2) 97.3 (96.4–98.2)
Central Asia
Kyrgyz Republic 2012 10 621 3.0 25.6 (24.8–26.4) 96.5 (95.8–97.2)
Latin America and the Caribbean
Dominican
Republic
2013 3543 1.2 23.1 (21.7–24.5) 99.5 (99.0–100)
Haiti 2012 22 721 0.7 24.5 (23.9–25.0) 98.6 (98.3–98.9)
Overall 732 844 1.5 32.4 (29.3–35.6) 96.5 (95.9–97.2)
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classified countries into low income or middle income using the
World Bank income classification system.
We employed a random effects meta-analysis to calculate
the pooled prevalence estimates of medical injection and
access to sterile injection equipment. We used a random effects
meta-analysis because it allows for heterogeneity across studies.
Our study population differs along geographic, regional and
socio-economic divides. Hence, even though the DHS used a sim-
ilar study design across countries, we expected heterogeneity.
Our choice of a random effects model was equally supported by
a test of heterogeneity of the DHS data obtained for the different
countries, which showed a high level of inconsistency (I2>50%).
Furthermore, we used sensitivity analysis to assess the effects
of outliers as well as test the robustness of our findings. We
performed a sensitivity analysis by excluding from our analysis
data from one country at a time, and the impact of excluding the
data was evaluated on the summary results.
We performed subgroup analyses to estimate the prevalence
of medical injection and access to sterile injection equipment by
some sociodemographic factors, including sex, age, type of res-
idence, wealth index, education, geographic region and income
classification.
Results
The DHS reports for 39 countries met the inclusion criteria for
this study and were meta-analysed (see Table 1). The pooled 12-
month prevalence estimate of medical injection among adults
15–49 y of age in LMICs was 32.4% (95% confidence inter-
val [CI] 29.3–35.6) (see Figure 2). Medical injections were more
common in Pakistan, Rwanda and Myanmar, with prevalence
estimates of 59.1% (95% CI 58.4–60.0), 56.4% (95% CI 55.7–
57.1) and 53.0% (95% CI 52.3–53.8), respectively (Table 1). The
sensitivity analysis performed by excluding data from Pakistan
yielded a prevalence estimate of 31.7% (95% CI 28.8–34.7).
This estimate was comparable to the overall pooled estimate.
There were substantial regional variations in the 12-month preva-
lence of medical injection, ranging from 13.5 (95% CI 12.8–14.2)
in West Asia to 42.7% (95% CI 35.0–50.4) in the South and
Southeast Asia.
Overall, 96.5% (95% CI 95.9–97.2) of individuals reported
having an injection with a syringe and needle taken from a
new, unopened package. Access to new syringes and needles
was comparatively less common in Pakistan, Comoros and
Afghanistan, with estimates of 86.0% (95% CI 85.3–86.7), 90.3%
(95% CI 88.8–91.8) and 90.9% (95% CI 90.4–91.4), respectively
(Table 1). There were also regional differences in access to sterile
injection devices (Table 2), with Latin America and the Caribbean
having the highest regional estimate of 99.0% (95% CI 98.2–
99.9) and South and Southeast Asia having the lowest estimate
(94.2% [95% CI 91.1–97.3]).
Based on age categorization (Table 2), we found the highest
prevalence of injection medication use among adults aged 25–
29 y (37.0% [95% CI 33.4–40.5]) and the lowest among adults
aged 40–49 y (30.4% [95% CI 27.0–33.8]). Adults in the highest
wealth index category had a higher prevalence of injection med-
ication use (35.3% [95% CI 32.1–38.4]) than their counterparts
in the lowest wealth index category (28.5% [95% CI 25.1–31.9]).
This pattern of results for the wealth index was similarly observed
for education level, where adults with at least a secondary edu-
cation had a higher prevalence of injection use (35.1% [95% CI
31.9–38.2]) than those without education (29.1% [95% CI 25.8–
32.3]). Interestingly, the highest prevalence of access to sterile
injection equipment was also recorded for adults in the highest
wealth index category (97.4% [95% CI 96.9–97.8]) compared
with those in the lowest wealth index category (95.2% [95% CI
94.2–96.3]), as well as adults with secondary/higher education
level (97.4% [95% CI 96.9–97.9]) compared with those with no
education (94.7% [95% CI 93.6–95.9]).
Discussion
In this study we estimated the prevalence of medical injections
and assessed the level of access to sterile injection equipment
in LMICs (potentially safe injections). The pooled prevalence of
medical injections was 32.4%. Higher prevalences were recorded
in South/Southeast Asia and sub-Saharan Africa regions. Pak-
istan, Rwanda and Myanmar were the countries with the highest
prevalence of medical injection use. The pooled and disaggre-
gated prevalence found in our study indicates that medical injec-
tions were considerably common in LMICs—suggesting varying
degrees of overuse of this mode of drug administration in the
countries assessed. Overall, 96.5% of adults in LMICs had access
to new, unopened syringes and needles. Thus 3.5%, approxi-
mately 1 in 29, medical injections were potentially unsafe in
LMICs.
The global prevalence of unsafe injection was estimated in
the year 2010 to be 5%.2,5 Our estimated pooled prevalence is
lower than this global prevalence—probably suggesting some
progress over time. However, given the risk associated (morbidity
and mortality) with unsafe injections,1,2,6–8,11,12 our estimated
pooled prevalence is considerable and calls for urgent action-
s/interventions. This position becomes even more important in
countries such as Pakistan, Comoros and Afghanistan, where we
found 14.0%, 9.7% and 9.1% prevalence of potentially unsafe
medical injections, respectively.
Generally, both patient- and provider-related factors are
known to drive overuse and subsequently unsafe medical
injections.3,17,18 For example, injection medications are often
thought (by patients and healthcare providers alike) to be
better, more effective or stronger than oral medicines.3,18
This observation, coupled with the profiteering tendencies of
some healthcare providers, may be relevant in explaining the
considerably high prevalence of medical injection found in the
present study. Poor knowledge of the risks associated with the
overuse of injections, sociocultural beliefs, financial constraints,
poor consumer protection, low awareness in the population and
poor regulation of medical practices have equally been noted to
contribute to the overuse of injection medications.3,17,18
The finding of a high prevalence of medical injections in
South/Southeast Asian countries is probably not surprising.
Available data have shown that injections are commonly used in
countries in these regions.17 For instance, in Pakistan (where we
found the highest prevalence of medical injections and unsafe
injections), and indeed in other countries in the South/Southeast
Asia region, economic incentives, patient preference (due to
misconceptions about injections), private practice (in particular)
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Figure 2. Meta-analysis for the prevalence of medical injection in low- and middle-income countries.
and prescribing by unqualified practitioners are among the major
factors contributing to the overuse of medical injections.17,19
Interventions, including regulatory and policy measures, directed
at these factors may contribute to reducing the overuse of
medical injections in this region and, by extension, other LMICs.
Our study reveals the place of the wealth index and education
level in medical injection medication use as well as in the level of
access to sterile injection equipment (potentially safe injection).
Rich respondents had a higher prevalence of medical injections
compared with the poor. Given that injections generally tend to
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Table 2. Prevalence of medical injection and access to new syringes and needles by demographic category
Category Number of participants
(N=732 844)
Prevalence of medical injection,
% (95% CI)
Access to sterile syringes and
needles, % (95% CI)
Sex
Male 218 991 27.1 (24.3–29.9) 96.4 (95.8–97.0)
Female 513 853 35.3 (31.8–38.7) 96.6 (95.9–97.2)
Age (y)a
15–24 267 732 30.7 (27.8–33.7) 96.5 (95.9–97.1)
25–29 125 606 37.0 (33.4–40.5) 96.9 (96.3–97.5)
30–39 199 956 34.3 (30.9–37.7) 96.7 (96.0–97.3)
40–49 138 252 30.4 (27.0–33.8) 96.2 (95.4–97.0)
Type of residencea
Urban 286 943 34.2 (31.2–37.2) 97.1 (96.6–97.6)
Rural 444 367 31.8 (28.4–35.2) 96.0 (95.3–96.8)
Education levela
No education 202 271 29.1 (25.8–32.3) 94.7 (93.6–95.9)
Primary 216 224 33.0 (29.5–36.4) 96.5 (95.9–97.1)
Secondary or higher 303 658 35.1 (31.9–38.2) 97.4 (96.9–97.9)
Wealth index
Lowest 125 962 28.5 (25.1–31.9) 95.2 (94.2–96.3)
Second 135 289 31.2 (27.8–34.6) 96.2 (95.4–97.0)
Middle 141 767 32.6 (29.2–36.0) 96.4 (95.7–97.1)
Fourth 155 385 34.2 (31.1–37.4) 97.0 (96.5–97.6)
Highest 174 441 35.3 (32.1–38.4) 97.4 (96.9–97.8)
Geographic region
Sub-Saharan Africa 518 077 31.8 (28.6–34.9) 96.9 (96.4–97.3)
Latin America and Caribbean 26 264 23.9 (22.5–25.3) 99.0 (98.2–99.9)
West Asia 8871 13.5 (12.8–14.2) 97.3 (96.4–98.2)
Central Asia 10 621 25.6 (24.8–26.4) 96.5 (95.8–97.2)
South and Southeast Asia 169 011 42.7 (35.0–50.4) 94.2 (91.1–97.3)
Country income level
Low income 386 292 31.4 (27.5–35.4) 96.4 (95.6–97.2)
Middle income 346 552 33.6 (28.4–38.7) 96.7 (95.7–97.8)
Overall 732 844 32.4 (29.3–35.6) 96.5 (95.9–97.2)
aCategory with some missing data.
be more expensive than oral medicines, this finding may well be
explained by the differences in financial capabilities, as in many
LMIC settings, healthcare services are paid for out of pocket.20,21
Not surprisingly, the rich also had greater access to sterile injec-
tion equipment compared with their poor counterparts, high-
lighting the possible disparity in access to quality healthcare that
is commonly reported between the rich and the poor.22–24 These
findings coupled with those in respect of education level suggest
that quality healthcare in many developing countries continues
to be associated with socio-economic level. A holistic approach to
safer injection thus needs to address socio-economic disparities
in access to quality healthcare services.
The use of nationally representative DHS data is the major
strength of this study; thus our findings are generalizable to the
adult population ages 15–49 y in the LMICs assessed in this
study. The application of a meta-analysis in providing pooled and
disaggregated estimates remains another important strength.
However, non-availability of relevant DHS data for our study
period (2010–2017) limited the number of LMICs considered in
the present study. Also, given that the DHS data largely captured
adults 15–49 y of age (an age group with lesser healthcare
needs compared with older adults), medical injection use may
have been underestimated. The data analysed were self-reported
and collected retrospectively, hence recall and social desirability
biases are likely. Nonetheless, restricting our analysis to informa-
tion provided for the period within 1 y preceding the surveys may
reduce the chances of recall bias.
Conclusions
Our study reveals a substantially high prevalence of medical
injection in LMICs, indicating that overuse of medical injec-
tion remains a considerable public health challenge in these
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countries. This overuse varies from region to region and from
one country to another, with Pakistan, Rwanda and Myanmar
ranking as countries where this was most commonly practised.
About 1 in 29 injections in LMICs is potentially unsafe. Urgent,
comprehensive and multisectoral interventions, including reg-
ulation of medical practices and policy measures aimed at
addressing socio-economic disparities in access to healthcare
services, are needed to stem the tide of unnecessary and unsafe
medical injection use in LMICs. In addition, there is a need to
educate both healthcare workers and patients on the dangers of
unsafe injection and the need for medical injection to be given
only when absolutely necessary. This is particularly critical in
countries/regions with a high prevalence of unsafe injection use
as found in the present study.
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